Key facts
- Monument Therapeutics’s last known valuation is $13.8M (Feb 2026).
- It has raised $8.6M; the latest was Accelerator/Incubator ($70K) in Feb 2026.
- Notable investors include Innovate UK, SyndicateRoom, Cambridge Angels, Meltwind Advisory, ACF Investors — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Monument Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Monument Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Monument Therapeutics
Developer of novel drugs intended to treat serious diseases of the central nervous system. The company's approach utilizes proprietary digital biomarkers to reduce heterogeneity and identify patients with homogenous underlying neurobiology, enabling researchers to focus on the advancement of neuroscience drugs in areas of unmet medical needs.
- Sector
- Healthcare
- HQ
- Macclesfield, United Kingdom
- Founded
- 2019
- Employees
- 7
- Website
- monumenttx.com/
- Ownership
- Privately Held (backing)
Monument Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Monument Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Monument Therapeutics in its N-PORT filings yet. We sweep new filings monthly.